{"nct_id":"NCT02939014","title":"Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)","status":"COMPLETED","status_verified_date":"2021-02","start_date":"2016-11-07","start_date_type":"ACTUAL","primary_completion_date":"2018-08-02","primary_completion_date_type":"ACTUAL","completion_date":"2020-02-03","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["TAK"]}